Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non‐small cell lung cancer harboring BRAF V600E mutation: A case report

Abstract In recent years, significant improvement has been made in the management of non‐small cell lung cancer (NSCLC), primarily driven by advances in targeted therapy and immunotherapy. Research on neoadjuvant targeted therapy has also experienced considerable development, primarily directed towa...

Full description

Bibliographic Details

Published in:	Thoracic Cancer
Main Authors:	Zhicheng Huang, Yadong Wang, Bowen Li, Yuan Xu, Guanghua Huang, Yang Song, Ji Li, Lan Song, Jinhua Wang, Rongxi Wang, Naixin Liang, Shanqing Li
Format:	Article
Language:	English
Published:	Wiley 2024-08-01
Subjects:	BRAF‐V600E neoadjuvant NSCLC
Online Access:	https://doi.org/10.1111/1759-7714.15409